LFCR 8-K SEC Filing Analysis

Latest settled — T+5d

LFCR ▼ -1.44% at T+5d

NEUTRAL call ✗ call lost -1.44% · α vs SPY -3.55% · entry $5.57 → $5.49

Next anchor: T+20d in 19d

Currently $5.35 · -3.95% from $5.57 entry

Entry anchored
Jun 5, 03:59 PM ET
via Databento tick

T+1d

+1.62%

call +1.62% · α +1.91%

$5.66

settled 9d ago

T+5d

-1.44%

call -1.44% · α -3.55%

$5.49

settled 5d ago

T+20d

—

call — · α —

—

in 19d

T+60d

—

call — · α —

—

in 3mo

Price Chart

Loading chart...

Executive Summary

Lifecore Biomedical filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the 2026 Stock Incentive Plan and elected nine directors. The new plan authorizes 2.5 million new shares plus any forfeited shares from the prior 2019 plan, becoming effective October 16, 2026. This is a routine governance filing with no material financial impact.

Actionable Insight

Monitor for future equity grants under the new plan, which could signal management's confidence or need for retention. No immediate trading catalyst — the plan is standard governance and becomes effective in October 2026.

Key Facts

Stockholders approved the 2026 Stock Incentive Plan with 22,724,492 votes for, 392,825 against, and 13,086 abstentions.
The 2026 Plan authorizes 2,500,000 new shares plus any forfeited shares from the 2019 Plan.
The 2026 Plan becomes effective October 16, 2026, replacing the 2019 Stock Incentive Plan.
All nine director nominees were elected, including two Series A Preferred directors elected solely by preferred stockholders.
KPMG LLP was ratified as independent auditor for FY 2026 with 33,760,879 votes for.
The say-on-pay advisory vote passed with 22,938,684 votes for.

Financial Impact

No financial impact; the 2026 Plan authorizes up to 2.5M new shares plus carryover from prior plan, but no immediate dilution or cash impact.

dilution

Risk Factors

Potential future dilution from equity awards under the 2026 Plan.
No material risk identified from this routine annual meeting filing.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

73% bullish (11 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001005286-26-000023
Document: lfcr-20260604.htm	0001005286-26-000023
Document: 0001005286-26-000023-index-headers.html	0001005286-26-000023
Document: 0001005286-26-000023-index.html	0001005286-26-000023
Document: 0001005286-26-000023.txt	0001005286-26-000023

7 reports for LFCR

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+20▲ +29.72%Mar 26, 2026

Filters

Reports for LFCR — sortable, filterable
	Type				Now
Jun 15, 2026 1d ago	Press Release BULLISH ★ 6/10	$5.49 $5.35	▼ −2.55%	▼ −1.95%	$5.35 (−2.55%)
Jun 5, 2026 11d ago	8-K NEUTRAL ★ 3/10	$5.57 $5.66	▲ +1.62%	▲ +1.91%	$5.35 (−3.95%)
Jun 2, 2026 14d ago	Press Release NEUTRAL ★ 4/10	$5.45 $5.67	▲ +4.04%	▲ +4.73%	$5.35 (−1.83%)
May 6, 2026 5w ago	8-K BEARISH ★ 7/10	$4.96 $4.77	▲ +3.83%	▲ +3.50%	$5.35 (−7.86%)
Mar 26, 2026 11w ago	Press Release BULLISH ★ 7/10	$3.87 $3.66	▼ −5.43%	▼ −3.75%	$5.35 (+38.24%)
Mar 16, 2026 13w ago	Press Release MIXED ★ 6/10	$4.37 $4.36	▼ −0.23%	▼ −0.50%	$5.35 (+22.43%)
Mar 4, 2026 14w ago	Press Release NEUTRAL ★ 4/10	$7.02 $6.96	▼ −0.85%	▲ +0.46%	$5.35 (−23.79%)

US Market Status

Market Closed — Opens in 5h 38m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access